ScreenerHero
GRALGRAIL Inc. Common Stock
NAS · US · Healthcare · Diagnostics & Research · grail.com
77.25USD+4.45%Mkt Cap: 3.30B $P/E: —

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individ…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$226.85BUSDP/E 33.1
DAP
Danaher Corporation
$142.58BUSDP/E 38.5
DHR
Danaher Corporation
$151.78BUSDP/E 38.6
LONN
Lonza Group AG
$47.21BUSDP/E 38.3
NTRA
Natera, Inc.
$46.86BUSD
IDXX
IDEXX Laboratories, Inc.
$44.35BUSDP/E 39.5
A
Agilent Technologies, Inc.
$44.14BUSDP/E 31.4
IQV
IQVIA Holdings Inc
$41.03BUSDP/E 31.0
WAT
Waters Corporation
$40.83BUSDP/E 105.8
ILU
Illumina, Inc.
$30.40BUSDP/E 40.4
ILMN
Illumina, Inc.
$30.95BUSDP/E 38.2
MTD
Mettler-Toledo International, Inc.
$28.55BUSDP/E 32.1
LH
Labcorp Holdings Inc.
$26.80BUSDP/E 27.4
DGX
Quest Diagnostics Incorporated
$26.68BUSDP/E 25.6
GH
Guardant Health, Inc.
$21.92BUSD
MEDP
Medpace Holdings, Inc.
$16.98BUSDP/E 35.8
ERF
Eurofins Scientific SE
$13.65BUSDP/E 25.3
CRL
Charles River Laboratories International, Inc.
$13.84BUSD
RVTY
Revvity Inc. Common Stock
$13.33BUSDP/E 57.4
BIM
bioMérieux S.A.
$9.55BUSDP/E 19.1

Key Statistics

Company
Market Cap3.30B $
Enterprise Value2.71B $
Revenue (TTM)165.26M $
Gross Profit-62.57M $
Net Income (TTM)-408.35M $
Revenue/Share4.114 USD
Last Price77.25 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees910
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.90
PEG—
EV/EBITDA-7.17
EV/Revenue16.41
P/S21.07
P/B1.37
EPS (TTM)-10.21
EPS (Forward)-9.87
52W Range
29.9553% of range118.84
52W High118.84 USD
52W Low29.95 USD
Profitability
Gross Margin-42.52%
Oper. Margin-332.00%
EBITDA Margin-229.02%
Profit Margin-277.47%
ROE-15.84%
ROA-13.97%
Growth
Revenue Growth25.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-299.01M $
CapEx (TTM)909.00K $
FCF Margin-62.68%
FCF Yield-3.14%
Net Debt-770.30M $
Net Debt/EBITDA2.04
Balance Sheet
Debt/Equity0.02
Current Ratio10.95
Quick Ratio10.55
Book Value/Sh56.93 USD
Cash/Share19.29 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.1 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)72.38 USD
Upside (mean)-6.3%
Target Range60.00 USD – 88.00 USD
$60.00-6.3% to mean$88.00
# Analysts8
Ownership
Shares Out.44.67M
Float34.29M
Insiders5.02%
Institutions86.78%
Short Interest
Short Ratio15.2d
Short % Float17.04%
Short % Out.16.77%
Shares Short7.49M
Short (prev mo.)7.75M
Technical
SMA 5068.33 (+13.1%)
SMA 20073.36 (+5.3%)
Beta3.25
S&P 52W Chg18.16%
Avg Vol (30d)630.00K
Avg Vol (10d)889.90K
Technical Indicators
RSI (14)55.6
MACD0.7566
MACD Signal0.7379
MACD Hist.+0.0186
BB Upper76.69 USD
BB Middle69.62 USD
BB Lower62.56 USD
BB Width20.29%
ATR (14)4.865 USD
Vol Ratio (20d)1.60x